Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Feb, 2017 | Pages:
153 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Hospital Acquired Pneumonia (HAP) - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hospital Acquired Pneumonia (HAP) - Pipeline Review, H1 2017, provides an overview of the Hospital Acquired Pneumonia (HAP) (Infectious Disease) pipeline landscape. Hospital Acquired Pneumonia (HAP) is defined as pneumonia acquired during hospital stay. Symptoms include cough, fever, shaking chills, confusion, headache and loss of appetite. Risk factors include chronic lung disease, cigarette smoking, dementia, stroke, brain injury, heart disease, liver cirrhosis and diabetes mellitus. Treatment includes antibiotics and healthy lifestyle. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hospital Acquired Pneumonia (HAP) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Hospital Acquired Pneumonia (HAP) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Hospital Acquired Pneumonia (HAP) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Hospital Acquired Pneumonia (HAP) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 8, 8, 7, 12, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively. Hospital Acquired Pneumonia (HAP) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Hospital Acquired Pneumonia (HAP) (Infectious Disease). - The pipeline guide reviews pipeline therapeutics for Hospital Acquired Pneumonia (HAP) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Hospital Acquired Pneumonia (HAP) (Infectious Disease) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Hospital Acquired Pneumonia (HAP) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Hospital Acquired Pneumonia (HAP) (Infectious Disease) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Hospital Acquired Pneumonia (HAP) (Infectious Disease). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Hospital Acquired Pneumonia (HAP) (Infectious Disease) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables List of Figures Introduction Global Markets Direct Report Coverage Hospital Acquired Pneumonia (HAP) - Overview Hospital Acquired Pneumonia (HAP) - Therapeutics Development Pipeline Overview Pipeline by Companies Pipeline by Universities/Institutes Products under Development by Companies Products under Development by Universities/Institutes Hospital Acquired Pneumonia (HAP) - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Hospital Acquired Pneumonia (HAP) - Companies Involved in Therapeutics Development Achaogen Inc Adenium Biotech ApS Aridis Pharmaceuticals LLC AstraZeneca Plc Bayer AG Cardeas Pharma Corp Destiny Pharma Ltd Dong-A Socio Holdings Co Ltd Lakewood-Amedex Inc MedImmune LLC Meiji Seika Pharma Co Ltd Melinta Therapeutics Inc Merck & Co Inc Motif Bio Plc Nabriva Therapeutics AG Polyphor Ltd Sealife PHARMA GMBH Shionogi & Co Ltd Tetraphase Pharmaceuticals Inc TGV-Inhalonix Inc The Medicines Company Theravance Biopharma Inc Wockhardt Ltd Zavante Therapeutics Inc Hospital Acquired Pneumonia (HAP) - Drug Profiles (amikacin sulfate + fosfomycin) - Drug Profile Product Description Mechanism Of Action R&D Progress (avibactam + ceftazidime) - Drug Profile Product Description Mechanism Of Action R&D Progress (avibactam sodium + aztreonam lysine) - Drug Profile Product Description Mechanism Of Action R&D Progress (ceftolozane sulfate + tazobactam sodium) - Drug Profile Product Description Mechanism Of Action R&D Progress (cilastatin sodium + imipenem + relebactam) - Drug Profile Product Description Mechanism Of Action R&D Progress (meropenem+ vaborbactam) - Drug Profile Product Description Mechanism Of Action R&D Progress (Pseudomonas + ventilator associated pneumonia) vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress AA-139 - Drug Profile Product Description Mechanism Of Action R&D Progress Aerucin - Drug Profile Product Description Mechanism Of Action R&D Progress alalevonadifloxacin - Drug Profile Product Description Mechanism Of Action R&D Progress amikacin sulfate - Drug Profile Product Description Mechanism Of Action R&D Progress arbekacin - Drug Profile Product Description Mechanism Of Action R&D Progress cefepime + zidebactam - Drug Profile Product Description Mechanism Of Action R&D Progress cefiderocol - Drug Profile Product Description Mechanism Of Action R&D Progress delafloxacin - Drug Profile Product Description Mechanism Of Action R&D Progress EBX-004 - Drug Profile Product Description Mechanism Of Action R&D Progress eravacycline - Drug Profile Product Description Mechanism Of Action R&D Progress exeporfinium chloride - Drug Profile Product Description Mechanism Of Action R&D Progress fosfomycin tromethamine - Drug Profile Product Description Mechanism Of Action R&D Progress iclaprim mesylate - Drug Profile Product Description Mechanism Of Action R&D Progress lefamulin acetate - Drug Profile Product Description Mechanism Of Action R&D Progress Levonadifloxacin - Drug Profile Product Description Mechanism Of Action R&D Progress MEDI-3902 - Drug Profile Product Description Mechanism Of Action R&D Progress Mul-1867 - Drug Profile Product Description Mechanism Of Action R&D Progress Nu-2 - Drug Profile Product Description Mechanism Of Action R&D Progress Nu-3 - Drug Profile Product Description Mechanism Of Action R&D Progress Panaecin - Drug Profile Product Description Mechanism Of Action R&D Progress panobacumab - Drug Profile Product Description Mechanism Of Action R&D Progress plazomicin sulfate - Drug Profile Product Description Mechanism Of Action R&D Progress POL-7001 - Drug Profile Product Description Mechanism Of Action R&D Progress Qn-2251 - Drug Profile Product Description Mechanism Of Action R&D Progress SLP-0905 - Drug Profile Product Description Mechanism Of Action R&D Progress sodium hypochlorite - Drug Profile Product Description Mechanism Of Action R&D Progress suvratoxumab - Drug Profile Product Description Mechanism Of Action R&D Progress tedizolid phosphate - Drug Profile Product Description Mechanism Of Action R&D Progress telavancin hydrochloride - Drug Profile Product Description Mechanism Of Action R&D Progress tosatoxumab - Drug Profile Product Description Mechanism Of Action R&D Progress Viritron VDX - Drug Profile Product Description Mechanism Of Action R&D Progress Hospital Acquired Pneumonia (HAP) - Dormant Projects Hospital Acquired Pneumonia (HAP) - Discontinued Products Hospital Acquired Pneumonia (HAP) - Product Development Milestones Featured News & Press Releases Oct 31, 2016: New Data On Iclaprim Released At Idweek 2016; Iclaprim Shown To Be Highly Potent Against SSSI And HABP Clinical Isolates Oct 31, 2016: Theravance Biopharma Presents Interim Data from Ongoing Telavancin Observational Use Registry (TOUR) at IDWeek 2016 Jul 21, 2016: AstraZeneca's antibiotic Zavicefta met primary endpoints in Phase III trial for treatment of hospital-acquired pneumonia Jun 28, 2016: New antibiotic Zavicefta approved in the European Union for patients with serious bacterial infections Jun 28, 2016: New antibiotic Zavicefta approved in the European Union for patients with serious bacterial infections Jun 20, 2016: Results of Phase 2 Study of Merck's Investigational Beta-Lactamase Inhibitor Relebactam in Combination with Imipenem/Cilastatin Presented at ASM Microbe May 16, 2016: New Data Analyses From Phase 3 ATTAIN Trials Support VIBATIV(R) (Telavancin) as a Treatment for Staphylococcus Aureus HABP/VABP, Including Cases Caused by MRSA May 16, 2016: New Data Analyses From Phase 3 ATTAIN Trials Support VIBATIV(R) (Telavancin) as a Treatment for Staphylococcus Aureus HABP/VABP, Including Cases Caused by MRSA May 11, 2016: Theravance Biopharma to Present New Data Analyses From Phase 3 ATTAIN Trials of VIBATIV (telavancin) in Treatment of HABP/VABP at American Thoracic Society 2016 International Conference May 11, 2016: Theravance Biopharma to Present New Data Analyses From Phase 3 ATTAIN Trials of VIBATIV (telavancin) in Treatment of HABP/VABP at American Thoracic Society 2016 International Conference Apr 11, 2016: VIBATIV (Telavancin) Shows Greater In Vitro Potency Against Difficult-to-Treat Pathogens Causing Hospital-Acquired Bacterial Pneumonia, Including MRSA, Compared to Alternative Antibiotic Treatments Apr 04, 2016: Theravance Biopharma to Present New Data Demonstrating Potent in vitro Activity for VIBATIV (telavancin) Against Difficult-to-Treat Infections, Including MRSA, at 2016 ECCMID Conference Feb 26, 2016: Pendopharm Launches Vibativ In Canada Feb 26, 2016: Pendopharm Launches Vibativ In Canada Feb 24, 2016: Aridis Pharmaceuticals Expands Patent Portfolio for Several Fully Human Monoclonal Antibodies Against Infectious Disease Targets Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer
List of Tables
Number of Products under Development for Hospital Acquired Pneumonia (HAP), H1 2017 Number of Products under Development by Companies, H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Number of Products under Development by Universities/Institutes, H1 2017 Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Products under Development by Companies, H1 2017 (Contd..2), H1 2017 Products under Development by Companies, H1 2017 (Contd..3), H1 2017 Products under Development by Universities/Institutes, H1 2017 Number of Products by Stage and Target, H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Hospital Acquired Pneumonia (HAP) - Pipeline by Achaogen Inc, H1 2017 Hospital Acquired Pneumonia (HAP) - Pipeline by Adenium Biotech ApS, H1 2017 Hospital Acquired Pneumonia (HAP) - Pipeline by Aridis Pharmaceuticals LLC, H1 2017 Hospital Acquired Pneumonia (HAP) - Pipeline by AstraZeneca Plc, H1 2017 Hospital Acquired Pneumonia (HAP) - Pipeline by Bayer AG, H1 2017 Hospital Acquired Pneumonia (HAP) - Pipeline by Cardeas Pharma Corp, H1 2017 Hospital Acquired Pneumonia (HAP) - Pipeline by Destiny Pharma Ltd, H1 2017 Hospital Acquired Pneumonia (HAP) - Pipeline by Dong-A Socio Holdings Co Ltd, H1 2017 Hospital Acquired Pneumonia (HAP) - Pipeline by Lakewood-Amedex Inc, H1 2017 Hospital Acquired Pneumonia (HAP) - Pipeline by MedImmune LLC, H1 2017 Hospital Acquired Pneumonia (HAP) - Pipeline by Meiji Seika Pharma Co Ltd, H1 2017 Hospital Acquired Pneumonia (HAP) - Pipeline by Melinta Therapeutics Inc, H1 2017 Hospital Acquired Pneumonia (HAP) - Pipeline by Merck & Co Inc, H1 2017 Hospital Acquired Pneumonia (HAP) - Pipeline by Motif Bio Plc, H1 2017 Hospital Acquired Pneumonia (HAP) - Pipeline by Nabriva Therapeutics AG, H1 2017 Hospital Acquired Pneumonia (HAP) - Pipeline by Polyphor Ltd, H1 2017 Hospital Acquired Pneumonia (HAP) - Pipeline by Sealife PHARMA GMBH, H1 2017 Hospital Acquired Pneumonia (HAP) - Pipeline by Shionogi & Co Ltd, H1 2017 Hospital Acquired Pneumonia (HAP) - Pipeline by Tetraphase Pharmaceuticals Inc, H1 2017 Hospital Acquired Pneumonia (HAP) - Pipeline by TGV-Inhalonix Inc, H1 2017 Hospital Acquired Pneumonia (HAP) - Pipeline by The Medicines Company, H1 2017 Hospital Acquired Pneumonia (HAP) - Pipeline by Theravance Biopharma Inc, H1 2017 Hospital Acquired Pneumonia (HAP) - Pipeline by Wockhardt Ltd, H1 2017 Hospital Acquired Pneumonia (HAP) - Pipeline by Zavante Therapeutics Inc, H1 2017 Hospital Acquired Pneumonia (HAP) - Dormant Projects, H1 2017 Hospital Acquired Pneumonia (HAP) - Discontinued Products, H1 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
